DeutschNewstral
Article
Financial Times on 2022-12-01 19:24
US equities: US cancer drug company accuses market makers of stock spoofing
Related news
- Chinese equities: China’s stock market drops to pre-pandemic lowFinancial Times
- Chinese equities: Foreign investors shun China stock rallyFinancial Times
US accuses Chinese trader of defrauding millions through futures spoofingSouth China Morning Post- US equities: Investors shun US consumer stocks over recession fearsFinancial Times
- Asian equities join US banking rally after SVB collapseFinancial Times
- Global equities slip as investors await US jobs reportFinancial Times
- US equities: Tesla’s dropping share price takes valuation below ExxonMobil’sFinancial Times
- Asian equities fall after sell-off in US bank sharesFinancial Times
- Fund management: US investors increase investments in foreign equitiesFinancial Times
- Equities: Interest rate worries leave doubts over durability of stock reboundFinancial Times
- Chinese equities: Beijing fund buys China bank shares in show of support for stock marketFinancial Times
- European equities: Charts that Matter. Investors hedge against a European stock market downturnFinancial Times
- LSE Group: when equities are no longer the stock in tradeFinancial Times
- US equities: opinion content. Markets Insight. Investors should be wary of US small-cap stocksFinancial Times
- US equities: US small cap stocks wilt in the heat of higher interest ratesFinancial Times
- US equities: Surf Air shares fall after first US direct listing in more than a yearFinancial Times
- Batteries: European battery makers welcome EU response to US subsidiesFinancial Times
- US equities: Algorithms prop up the market as fretful humans sit out the uncertaintyFinancial Times
- European equities edge up as investors await US retail sales data and earningsFinancial Times
- FT live news: Asia equities follow US higher after debt ceiling vote triggers gainsFinancial Times